araag2/HINT huggingface dataset:
Clinical trial NCT01095731 (phase 2, status: completed)
Conditions: aneurysmal subarachnoid hemorrhage
ICD codes: I60.8, I60.9, I69.020, I69.021, I69.022, I69.090, I69.091
Drugs: tiopronin, placebo
SMILES: CC(S)C(O)=NCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Admitted to a recruiting center with aneurysmal subarachnoid hemorrhage

          -  Ability to initiate study drug treatment within 96 hours of aSAH onset.

          -  Ability to provide either informed or surrogate consent

        Exclusion Criteria:

          -  Hypersensitivity to penicillamine

          -  Creatinine level greater than 1.5/mm^3 on admission

          -  Platelet count of less than 100,000/mm^3 on admission

          -  White blood cell count of less than 3.5/mm^3 on admission

          -  AST or ALT of greater than 60/L on admission or history of liver failure

          -  Pregnancy

          -  History of lupus, Goodpasture's syndrome, myasthenia gravis, pemphigus, nephrotic
             syndrome, glomerulonephritis, or renal failure

          -  Patients considered unable to comply with the protocol
Clinical trial NCT00670202 (phase 2, status: terminated)
Conditions: carotid stenosis
ICD codes: I65.21, I65.22, I65.23, I65.29, I63.231, I63.232, I63.233
Drugs: fasudil hydrochloride, placebo oral tablet
SMILES: O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2, CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    slow enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with >= 70% carotid stenosis (unilateral or bilateral) who are scheduled to
             undergo elective carotid endarterectomy

          -  Age >= 18 years

          -  Agreement of the operating surgeon for patient to participate

        Exclusion Criteria:

          -  Surgery scheduled < 14 days after randomization

          -  Pregnancy

          -  ALT, GGT > 3x upper limit of normal (ULN)

          -  Creatinine > 3.5 mg/dL

          -  Prior intolerance to statins

          -  Reluctance to add or change dosage of statin therapy during study
Clinical trial NCT00481325 (phase 2/phase 3, status: completed)
Conditions: generalized anxiety disorder
ICD codes: F41.1
Drugs: pexacerfont, escitalopram, placebo
SMILES: CC[C@@H](C)NC1=NC(C)=NC2=C(C(C)=NN12)C1=CC=C(OC)N=C1C, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatient women ages 18-65 meeting Diagnostic and Statistical Manual of Mental
             Disorders Manual, Fourth Edition, Text Revision (DSM-IV TR) criteria for Generalized
             Anxiety Disorder (GAD), either moderate or severe (300.02)

        Exclusion Criteria:

          -  Males

          -  Patients who report a history of inadequate response to three or more adequate trials
             of any selective Serotonin reuptake inhibitors (SSRIs) for GAD within the last three
             years
Clinical trial NCT00335829 (phase 2, status: completed)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: chemotherapy, embolization therapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed* hepatocellular carcinoma

               -  Unresectable disease

               -  Child's class A or B with liver-predominant and asymptomatic extrahepatic disease
                  NOTE: *A highly suspicious liver mass on CT scan or MRI in the presence of alpha
                  fetoprotein > 200 mg/dL may be used as alternative diagnostic criterion

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Absolute neutrophil count > 1,500/mm³

          -  Platelet count > 50,000/mm³

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5.0 times upper
             limit of normal (ULN)

          -  Bilirubin ≤ 5.0 mg/dL

          -  Creatinine normal OR creatinine clearance > 50 mL/min

          -  No significant traumatic injury within the past 28 days

          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
             the past 6 months

          -  No serious, nonhealing wound, ulcer, or bone fracture

        PRIOR CONCURRENT THERAPY:

          -  No major surgery or open biopsy within the past 28 days

          -  No minor surgery (e.g., fine-needle aspirations or core biopsies) within the past 7
             days

          -  No chemotherapy within the past 4 weeks

          -  No radiotherapy within the past 21 days

          -  No concurrent major surgery

          -  No other concurrent chemotherapy

          -  No other concurrent investigational drugs
Clinical trial NCT00652496 (phase 2, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost 0.01% ophthalmic solution, bimatoprost 0.015% formulation 1 ophthalmic solution, bimatoprost 0.015% formulation 2 ophthalmic solution, bimatoprost 0.02% ophthalmic solution, bimatoprost 0.03% ophthalmic solution
SMILES: CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Ocular hypertension or glaucoma in both eyes

          -  Require IOP-lowering therapy in each eye

        Exclusion Criteria:

          -  Uncontrolled systemic disease

          -  Known allergy or hypersensitivity to bimatoprost
Clinical trial NCT00147966 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Active rheumatoid arthritis

          -  Use of concomitant methotrexate

        Exclusion Criteria:

          -  Use of disease-modifying anti-rheumatic drugs (DMARDs)/biologics other than
             methotrexate

          -  Serious medical conditions that would preclude the use of the treating agent
Clinical trial NCT00479466 (phase 2, status: terminated)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mk0893, metformin, placebo to mk0893, placebo to metformin
SMILES: COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, CSCC[C@H](N)C(O)=O, COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, CN(C)C(=N)NC(N)=N
Reason stopped: 
    sufficient data regarding the dose-response to mk-0893 had been obtained from the first cohort
    of the study to assess the safety and efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while
             either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose
             combination therapy

        Exclusion Criteria:

          -  Patients have a history of Type 1 Diabetes Mellitus

          -  Patients taking insulin or thiazolidinedione (TZD, a peroxisome proliferator-activated
             receptor [PPAR]-gamma agonist)

          -  Patients who have a contraindication to metformin
Clinical trial NCT00539513 (phase 2, status: terminated)
Conditions: obsessive-compulsive disorder
ICD codes: F42.8, F42.9, F60.5
Drugs: n-acetylcysteine, placebo
SMILES: CC(=O)N[C@@H](CS)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    researchers terminated study due to limited enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  DSM-IV diagnosis of OCD, confirmed by SCID-IV; symptoms of at least 1 year duration

          -  moderate to severe OCD symptoms (Y-BOCS > 16)

          -  documented failure of an adequate trial of an SSRI

          -  agreement to engage in a reliable form of birth control (women only)

        Exclusion Criteria:

          -  primary diagnosis of a psychotic disorder

          -  active substance abuse or dependence

          -  unstable medical condition

          -  prior exposure to N-Acetylcysteine

          -  prior psychosurgery

          -  pregnancy, breastfeeding, or intent to become pregnant during study

          -  liver function tests (LFTs) elevated to more than 2x the upper limit of normal

          -  evidence of active liver disease

          -  seizure disorder

          -  active suicidal ideation
Clinical trial NCT00514527 (phase 2, status: completed)
Conditions: staphylococcal skin infections, wounds and injuries, abscess, cellulitis, streptococcal infections
ICD codes: G00.3, M00.09, A05.0, M00.08, L00, M00.00, M00.011, P15.8, T07.XXXS, P12.89, P13.1, P14.3, T07.XXXA, T07.XXXD, J36, K61.0, K61.1, K61.2, K61.31, K61.4, K61.5, L03.213, L03.90, L03.211, L03.221, L03.314, L03.315, L03.316
Drugs: oritavancin
SMILES: CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
Eligibility criteria:

        Inclusion Criteria

          -  Complicated skin and skin structure infection, presumed or proven to be caused by
             gram-positive pathogen(s).

          -  Patients, ages 18 years and older, must not be below normal body weight or morbidly
             obese.

          -  Female patients must not be pregnant at time of enrollment and must agree to a
             reliable method of birth control during the study and for 6 months following the last
             dose of study drug.

        Exclusion Criteria:

        Patients:

          -  with a condition which would prevent performing protocol safety and efficacy
             assessments.

          -  who have received antibiotics for more than 24 hours within the last 3 days.

          -  with an infection involving deep tissues or unlikely to be caused by gram positive
             bacteria

          -  who are nursing and will not stop nursing for at least 6 months

          -  with a prior allergic reaction to glycopeptides (e.g. vancomycin)

          -  with any of the following:

               1. toxic shock syndrome or toxic-like syndrome

               2. presumed or proven infection caused by Clostridium species

               3. bone infections

               4. ischemic or gangrenous ulcers or wounds

               5. infections caused only by gram-negative bacteria

               6. infection of an artificial joint that cannot be removed

               7. infection of the scrotum, perineum or perianal region

               8. infection of a severe burn wound

               9. severe ear infection involving bone and/or cartilage

              10. infection following injury in water possibly containing Vibrio species or
                  following a history of eating raw oysters within 1 week prior to disease onset
Clinical trial NCT00395772 (phase 2, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: xarelto (rivaroxaban, bay59-7939), xarelto (rivaroxaban, bay59-7939), xarelto (rivaroxaban, bay59-7939), (lmw) heparin + vitamin k antagonist
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed acute symptomatic DVT, i.e. proximal or extensive calf-vein thrombosis
             involving at least the upper third part of the calf veins, without concomitant
             symptomatic PE

          -  Written informed consent

        Exclusion Criteria:

          -  Legal lower age limitations (country specific)

          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the
             current episode of DVT

          -  Other indication for VKA than PE/DVT

          -  More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW)
             heparin or more than a single dose of VKA prior to randomization

          -  Participation in another pharmacotherapeutic study within the prior 30 days

          -  Creatinine clearance < 30 mL/min, impaired liver function (transaminases > 2 x ULN),
             or bacterial endocarditis

          -  Life expectancy < 3 months

          -  Active bleeding or high risk for bleeding contraindicating treatment with (LMW)
             heparin

          -  Uncontrolled hypertension: systolic blood pressure > 200 mmHg and diastolic blood
             pressure > 110 mmHg

          -  Pregnancy or childbearing potential without proper contraceptive measures

          -  Any other contraindication listed in the labeling of warfarin, acenocoumarol,
             phenprocoumon, fluindione, UFH, enoxaparin, or tinzaparin

          -  Systemic treatment with azole compounds or other strong CYP3A4 inhibitors (e.g.
             ketoconazole, fluconazol, itraconazole, HIV protease inhibitors) within 4 days prior
             to randomization and during the study
Clinical trial NCT00475735 (phase 2, status: completed)
Conditions: attention-deficit/hyperactivity disorder (adhd)
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: mk0249, concerta (methylphenidate), placebo
SMILES: CC1=NC2=CC=CC(=C2C(=O)N1C1=CC=C(OCCCN2CCCC2)C=C1)C(F)(F)F, COC(=O)C(C1CCCCN1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is between 18 and 55 years of age (inclusive)

          -  Patient is an adult with a current DSM-IV diagnosis of ADHD of inattentive or combined
             subtype, as assessed via a structured interview using the ACDS and AISRS

          -  Females of child-bearing potential must use acceptable methods of birth control during
             the study and for 1 month post-therapy

        Exclusion Criteria:

          -  Patient has a history of a neurological disorder resulting in ongoing impairment

          -  Patient has a lifetime history of a psychotic disorder, bipolar disorder, or
             post-traumatic stress disorder

          -  Patient has evidence of ongoing depression

          -  Patient is sensitive or allergic to methylphenidate

          -  Patient has glaucoma

          -  Patient has a previous history of narrowing or blockage of the GI tract

          -  Patient has a history of a sleep disorder (e.g., insomnia, sleep apnea, nightmares, or
             night terrors) within 6 months prior to screening

          -  Patient has a history of a cardiovascular disorder within 6 months prior to screening

          -  Patient has moderate or severe persistent asthma

          -  Patient has a history of substance abuse or dependence not in sustained full remission
             for at least one year according to DSM-IV

          -  Patient has taken part in a research study within the past 30 days of signing informed
             consent
Clinical trial NCT01472198 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: simtuzumab, gemcitabine, placebo to match simtuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Initial diagnosis of metastatic pancreatic cancer must have occurred ≤6 weeks prior to
             the completion of screening.

          -  The presence of measurable metastatic pancreatic cancer documented by contrast
             enhanced CT (or MRI) scan in addition to 1 of the following:

               1. Histological diagnosis of pancreatic adenocarcinoma confirmed by pathologist OR

               2. Pathologist confirmed histological/cytological diagnosis of adenocarcinoma
                  consistent with pancreatic origin in conjunction with either:

                    1. The presence of a mass in the pancreas OR

                    2. A history of resected pancreatic carcinoma

          -  Measurable disease per RECIST (ver. 1.1)

          -  ECOG Performance Status of 0 or 1.

          -  Adequate hepatic, hematologic and renal functions.

        Exclusion Criteria:

          -  A history or evidence of clinically significant disorder other than metastatic cancer
             of the pancreas.

          -  A diagnosis of pancreatic islet neoplasms.

          -  Subject has undergone major surgery other than diagnosis surgery within 4 weeks of
             randomization

          -  Presence of biliary obstruction requiring external drainage

          -  Brain metastases.

          -  Unstable cardiovascular function within the last 6 months of screening

          -  Clinically active liver disease, including active viral hepatitis (HBV or HCV) or
             cirrhosis

          -  Known HIV infection.

          -  Uncontrolled hypertension at Screening

          -  History or presence of any form of cancer, other than pancreatic cancer, within the 3
             years prior to enrollment

          -  Prior or concurrent anti-tumor therapy (chemotherapy, antibody therapy, molecular
             targeted therapy, retinoid therapy, hormonal therapy) for the treatment of inoperable
             locally advanced or metastatic pancreatic cancer; prior radiotherapy and chemotherapy
             given as pre-operative neoadjuvant therapy or radio sensitizers for locally advanced
             pancreatic cancer are allowed.

          -  Uncontrolled systemic fungal, bacterial or viral infection

          -  Participation in an investigational drug or device trial with therapeutic intent
             within 30 days prior to study
Clinical trial NCT00358826 (phase 2, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: via-2291, placebo
SMILES: C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients are to be of non-childbearing potential

          -  Patient has suffered an ST elevation myocardial infarction (MI), non-ST elevation MI,
             or unstable angina 21 days (±3 days) prior to study randomization

          -  Patient has documented coronary artery disease

        Exclusion Criteria:

          -  Renal insufficiency defined as creatinine >1.5 x upper limit of normal (ULN)

          -  Cirrhosis, recent hepatitis, ALT >1.5 x ULN or ALT > 1 x ULN and at least one other
             liver function test

          -  Uncontrolled diabetes mellitus within 1 month prior to study screening

          -  Congestive heart failure (CHF) defined by the New York Heart Association as functional
             Class III or IV

          -  Previous coronary artery bypass graft (CABG) surgery

          -  Planned additional cardiac intervention

          -  Recurrence of ST elevation MI, non-ST elevation MI, or unstable angina less than 18
             days prior to randomization

          -  Current atrial fibrillation, atrial flutter, or frequent premature ventricular
             contractions

          -  Acetaminophen use in any form in the 7 days before enrollment
Clinical trial NCT02004886 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mk-0893, metformin, placebo, placebo
SMILES: COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Not currently on antihyperglycemic agent (AHA) or AHA monotherapy (not to include
             treatment with insulin or thiazolidinediones [i.e., peroxisome proliferator activated
             receptor-gamma, PPARγ agents])

          -  male or a female of non-childbearing potential. Women must be postmenopausal or
             premenopausal and documented surgically sterilized

          -  A body mass index (BMI) that is > 20 and ≤ 40 kg/m2

        Exclusion Criteria:

          -  History of type 1 diabetes or assessed by the investigator as possibly having type 1
             diabetes

          -  History of ketoacidosis; clinically unstable or rapidly progressive diabetic
             retinopathy, nephropathy, neuropathy

          -  Treatment for diabetes within 3 months of study participation with combination
             anti-hyperglycemic therapy, insulin or thiazolidinediones (e.g., rosiglitazone or
             pioglitazone)

          -  oral corticosteroid medications within 2 weeks prior to study participation, or
             requires digoxin, warfarin, warfarin-like anticoagulants, theophylline,
             anti-dysrhythmic or anti-seizure medications, immunosuppressants, or anti-neoplastic
             agents, or herbal remedies

          -  History of acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus
             (HIV)

          -  History of gastrointestinal problems or disorders or extensive bowel or gastric
             surgery

          -  History of significant or unstable cardiovascular disease

          -  History of neoplastic disease

          -  History of hepatic disease

          -  History of seizures, epilepsy or other neurologic disease

          -  History of myelodysplastic or pre-leukemic disorders or other severe hematological
             disorder
Clinical trial NCT00097760 (phase 2, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: natalizumab, natalizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of MS as defined by McDonald et al., criteria # 1-4

          -  Between the ages of 18 and 55, inclusive

          -  Baseline EDSS score between 0.0 and 5.0, inclusive

          -  Have been treated with GA for at least the 12 months prior to randomization

        Exclusion Criteria:

          -  Primary progressive, secondary progressive or progressive relapsing MS

          -  MS relapse has occurred within the 50 days prior to randomization

          -  A clinically significant infectious illness

          -  History of, or abnormal lab result indicative of significant disease that would
             preclude the administration of a recombinant humanized antibody immunomodulating agent
             or GA for 20 weeks.